Anixa Biosciences doses first patient in Phase 1 CAR-T trial for ovarian cancer

Anixa Biosciences Inc

First patient dosed in Phase 1 trial of novel CER-T therapy for ovarian cancer at Moffitt Cancer Center.
Dose-escalation study to evaluate safety, maximum tolerated dose, and preliminary efficacy.
Trial targets follicle stimulating hormone receptor (FSHR) on ovarian cells.
Up to 48 patients may be enrolled in the study.
CER-T approach differs from traditional CAR-T by targeting an endocrine receptor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.